Background-The anthracycline doxorubicin is an effective chemotherapeutic agent used to treat pediatric cancers but is associated with cardiotoxicity that can manifest many years after the initial exposure. To date, very little is known about the mechanism of this late-onset cardiotoxicity. Methods and Results-To understand this problem, we developed a pediatric model of late-onset doxorubicin-induced cardiotoxicity in which juvenile mice were exposed to doxorubicin, using a cumulative dose that did not induce acute cardiotoxicity. These mice developed normally and had no obvious cardiac abnormalities as adults. However, evaluation of the vasculature revealed that juvenile doxorubicin exposure impaired vascular development, resulting in abnormal vascular architecture in the hearts with less branching and decreased capillary density. Both physiological and pathological stress induced late-onset cardiotoxicity in the adult doxorubicin-treated mice. Moreover, adult mice subjected to myocardial infarction developed rapid heart failure, which correlated with a failure to increase capillary density in the injured area. Progenitor cells participate in regeneration and blood vessel formation after a myocardial infarction, but doxorubicin-treated mice had fewer progenitor cells in the infarct border zone. Interestingly, doxorubicin treatment reduced proliferation and differentiation of the progenitor cells into cells of cardiac lineages. Conclusions-Our data suggest that anthracycline treatment impairs vascular development as well as progenitor cell function in the young heart, resulting in an adult heart that is more susceptible to stress. (Circulation. 2010;121:675-683.)
A nthracyclines are very effective antineoplastic agents with a broad antitumor spectrum, including many solid tumors and leukemias. Unfortunately, their clinical use is limited by progressive and dose-related cardiotoxicity that may not manifest itself until many years after treatment. 1 Three distinct types of anthracycline-induced cardiotoxicity have been described: acute, early-onset, and late-onset cardiotoxicity. 2 Acute anthracycline-induced cardiotoxicity occurs typically within the first week of treatment and is usually reversible on discontinuation of treatment. Early-onset cardiotoxicity usually presents within a year after completion of treatment, and most patients who develop significant cardiotoxicity have a chronic dilated cardiomyopathy. 3 Late-onset cardiotoxicity is characterized by a latent period during which cardiac function appears normal and the patient is asymptomatic. This type of cardiotoxicity can manifest as much as 15 years after treatment and is characterized by progressive left ventricular dysfunction leading to irreversible congestive heart failure. Heart failure is often precipitated by events such as exercise, pregnancy, and acute viral infection. 4, 5 This latent cardiac toxicity presents a particularly challenging dilemma when pediatric cancers are treated. The only known risk factors for late-onset cardiotoxicity are cumulative anthracycline dose and younger age at the time of treatment. 6 The frequency of cardiotoxic effects has been reported to be as high as 57% among survivors of childhood cancer, 7 and a survey by the Pediatric Cardiomyopathy Registry shows that Ͼ15% of all adult patients with cardiomyopathy were previously treated for cancer during childhood or adolescence. 8 gation for many years. However, the mechanisms underlying the cardiotoxic effects are still not fully understood, and multiple mechanisms have been proposed to explain the actions of anthracyclines. These include reactive oxygen species production, apoptosis, disruption in DNA replication, and transcription. 9, 10 In contrast, very little is known about the underlying mechanisms of late-onset cardiotoxicity, and no animal model has been developed that recapitulates this clinical scenario.
In this study, we developed a juvenile mouse model of anthracycline-mediated late-onset cardiotoxicity. Juvenile mice exposed to modest doses of doxorubicin develop normally and have no obvious cardiac abnormalities as adults. However, these hearts have abnormal vasculature and a reduced number of progenitor cells, which correlated with an increased sensitivity to physiological and pathological stimulus.
Methods

Animals and Experimental Protocol
FVB/N mice were injected at a postnatal age of 5, 10, 15, and 20 days with an intraperitoneal injection of either doxorubicin (Sigma, St Louis, Mo) or saline. Doxorubicin was injected in a volume of 30 to 40 L. The first 2 doses at 5 and 10 days of age were at a concentration of 1 mg/kg, and the last 2 injections at 15 and 20 days after birth were 0.5 mg/kg. Control animals were injected with an equivalent volume of saline. Animals were observed daily and weighed weekly. At 8 to 12 weeks of age, the animals were used for experiments.
Swimming Protocol
Eight-to 12-week old saline-treated (nϭ10) and doxorubicin-treated (nϭ10) mice swam together in a glass tank in 34°C water with a light current to prevent floating. To get accustomed to swimming, the mice initially swam for 15 minutes per day. Sessions were gradually increased to 90 minutes twice a day. After 1 week, mice were swimming for 90 minutes twice a day for 14 days separated by a 2-hour rest period. 11 The total swimming time was 21 days. One group of saline-injected (nϭ10) and doxorubicin-injected (nϭ10) mice was used as sedentary controls. Twenty-four hours after completion of the 21-day swimming regimen, mice were evaluated for cardiac function and then euthanized for tissue harvest.
In Vivo Coronary Artery Ligation and Infarct Size Measurement
Coronary occlusion was performed as described previously. 12 Briefly, 8-to 12-week-old saline-treated (nϭ29) and doxorubicintreated (nϭ37) mice were anesthetized with isoflurane, intubated, and ventilated. Pressure-controlled ventilation (Harvard Apparatus) was maintained at 9 cm H 2 O throughout the procedure. An 8-0 silk suture was placed around the proximal left coronary artery and then ligated. The suture was left in place, and the animal was immediately closed up. Sham-operated mice had a suture placed around the left anterior descending artery that was not tightened. Only mice that 
Isolation of Cardiac Progenitor Cells
Isolation of c-kit-positive progenitor cells was done with the use of a protocol adapted from Beltrami et al. 14 Briefly, mouse hearts from 7-day-old mouse pups were minced and digested with Collagenase II in J-MEM (supplemented with HEPES, glutamine, taurine, and insulin). The digested heart pieces were filtered through a 30-m filter and incubated with anti-CD117-conjugated Miltenyi Biotec Microbeads. C-kit-positive cells were isolated by passing cells over a Miltenyi Biotec MiniMACS sorting column. The cells were cultured in Dulbecco's modified Eagle's medium and Ham's F12 (ratio 1:1), basic fibroblast growth factor (10 ng/mL), epidermal growth factor (20 ng/mL), leukemia inhibitory factor (10 ng/mL), HEPES (5 mmol/L), and insulin-transferrin-selenite for up to 4 passages.
Statistical Analysis
All values are expressed as meanϮSD. Time, treatments, and procedures were approximately normally distributed and analyzed with the use of ANOVA followed by t tests. Two-factor repeatedmeasures ANOVA was utilized for mouse weights and Masson trichrome staining. All other variables were analyzed with parametric testing (Student t test). Survival rate was analyzed by the Kaplan-Meier method with the log-rank test. PϽ0.05 was considered significant. In the figure legends, n is equal to the sample size per group. All tests were performed with the use of GraphPad Prism 5. Detailed experimental protocols are described in the online-only Data Supplement.
Results
To study late-onset cardiotoxicity, mice were injected with either saline or doxorubicin at 5, 10, 15, and 20 days after birth ( Figure 1A ). No acute cardiotoxicity was observed and myocytes appeared normal ( Figure 1B ) and there was no increase in apoptosis ( Figure 1C ) immediately after completion of the injections. Adult hearts from saline-and doxorubicin-treated mice appeared morphologically normal ( Figure 1D ). Doxorubicin-mediated cardiotoxicity is characterized by disorganized myofibrils, increased vacuolization, and swelling of organelles. 15 However, electron microscopy revealed no degenerative changes suggestive of doxorubicinmediated toxicity in cardiac myocytes ( Figure 1E ). Doxorubicin treatment resulted in slower weight gain in pups compared with saline treatment, but this difference diminished as the mice matured ( Figure I in the online-only Data Supplement). There were no cardiac hypertrophy ( Figure II in the online-only Data Supplement) and no difference in cardiac function in doxorubicin-treated mice in adulthood compared with saline-treated mice (Table) . Because doxorubicin has potent antiangiogenic effects, 16 we investigated whether doxorubicin treatment affected vascular development in the juvenile heart. Measurement of blood flow and visualization of the coronary branching pattern revealed that juvenile doxorubicin exposure resulted in reduced blood flow ( Figure 2A ) and reduced coronary branching ( Figure 2B ) in the adult heart. Although major vessels in doxorubicin-treated hearts appeared to have narrower lumen than saline-treated hearts, examination of the vessels revealed no differences in thickness and composition ( Figure IIIA and IIIB in the online-only Data Supplement). In a time course study, capillary density was unaffected in the young animal during (at day 11) and immediately after completion (at day 21) of the doxorubicin injections. However, at day 40 and 60, capillary densities were significantly reduced in the doxorubicin-treated animals ( Figure 2C ). The vascular endothelial growth factor (VEGF) is involved in development of vessels and stimulates recruitment and pro- Juvenile doxorubicin (DOX) treatment increases susceptibility to exercise in adulthood. A, Swimming for 21 days induces cardiac hypertrophy in doxorubicintreated mice as measured by the ratio of heart weight (HW) to body weight (BW) (nϭ9). B, Hematoxylin-eosin staining of heart sections after swimming. C, Hematoxylin-eosin staining of doxorubicin heart sections after swimming. D, Masson trichrome staining of heart sections after swimming. E, Measurement of ventricular end-diastolic pressure (mm Hg) in sedentary or swimming mice (nϭ5 to 8).
liferation of endothelial cells. 17 Interestingly, myocardial VEGF expression was significantly reduced in the heart at day 21 and remained reduced into adulthood ( Figure 2D and 2E), suggesting that juvenile doxorubicin exposure might affect vascular development by interfering with VEGF signaling. VEGF levels in the plasma were not different between the saline-and doxorubicin-treated animals at any time point (Figure IV in the online-only Data Supplement).
Sufficient vasculature is important for the heart to adapt to increased workload such as exercise. To investigate whether the doxorubicin-exposed mice were more sensitive to exercise, we subjected saline-and doxorubicin-treated adult mice to endurance swimming. After 21 days of swimming, hearts of doxorubicin-injected mice displayed cardiac hypertrophy ( Figure 3A) and dilation of the left ventricle ( Figure 3B ). In contrast, saline-treated mice did not display any significant hypertrophy or dilatation of the ventricle after the swimming, confirming that cardiac hypertrophy was attributable to the combination of doxorubicin treatment and exercise. Hematoxylin-eosin staining revealed many areas of myofibril disarray in doxorubicin-exposed hearts after swimming ( Figure  3C ). In addition, hearts from doxorubicin-treated mice had increased fibrosis after swimming ( Figure 3D ). Hemodynamic analysis of mice showed that the ventricular end-diastolic pressure was reduced in swimming saline-treated mice, whereas it was increased after swimming in doxorubicin-treated mice ( Figure 3F ). These data demonstrate that modest doses of doxorubicin in young mice result in decreased capability of the hearts to adapt to increased workload in adulthood.
Moreover, neovascularization in the border zone after myocardial infarction (MI) is an important beneficial response that limits the development of left ventricular remodeling and deterioration to heart failure. 18 To investigate whether juvenile doxorubicin exposure impaired the neovascularization response, adult saline-and doxorubicin-treated mice were subjected to MI by permanent ligation of the left anterior descending coronary artery. Interestingly, doxorubicintreated mice were highly sensitive to MI, and the survival rate of doxorubicin-treated mice was only Ϸ25% compared with Ϸ80% for the saline-treated mice ( Figure 4A ). Doxorubicinexposed mice had larger (but not significant) infarct size (80.3%) than saline-treated mice (71.3%) ( Figure 4B and 4C) . More importantly, doxorubicin-exposed mice had significantly larger area at risk, suggesting differences in the vasculature ( Figure 4D ). Doxorubicin-treated mice also had extensive fibrosis compared with saline-treated mice after MI ( Figure 4E ). Even though there was no increase in fibrosis under nonstressed conditions between the saline-and doxorubicin-treated hearts (data not shown), the amount of fibrosis was significantly increased in the remote (nonrisk) area in the doxorubicin-treated heart. In addition, measurement of capillary density in the infarct border zone 4 days after MI showed that doxorubicin-exposed mice had reduced neovascularization after MI compared with saline-treated mice ( Figure 5A ). In addition, the abundance of staining for ␣-smooth muscle actin was attenuated in doxorubicin-treated hearts in the border zone ( Figure 5B) . Visualization of the vasculature after MI confirmed that doxorubicin-treated hearts had reduced vessel formation in the border zone ( Figure 5C ). These results suggest that doxorubicin treatment affects vascular development in the juvenile heart and puts the adult heart at greater risk for ischemic injury.
MI is associated with migration of progenitor cells into the damaged area, where they participate in regeneration and blood vessel formation. 19 -21 Immunostaining of adult salinetreated heart sections for the presence of cells positive for the common stem cell marker c-kit 22 revealed small c-kitϩ cells with high nucleus/cytoplasm ratio in the border zone of the infarct by 4 days after MI ( Figure 6 ). Interestingly, there were significantly fewer c-kitϩ cells in the border zone of animals that had been exposed to doxorubicin as pups ( Figure 6C ). We also investigated whether the MI stimulated differentiation of the cardiac progenitor cells into cells of different lineages, as has been reported previously. [23] [24] [25] [26] At 7 days after MI, 63% and 44% of c-kitϩ cells stained positive for endothelial cell lineage markers Flk-1 and CD31, respectively, in saline-treated hearts. Importantly, only 29% and 21% of the c-kitϩ cells stained positive for Flk-1 and CD31 in doxorubicin-treated hearts (Figure V in the online-only Data Supplement). In saline-treated hearts, 53% of the c-kitϩ cells were positive for GATA-4, and 62% were positive for MEF2C, suggesting that these cells are committed to a myocyte lineage ( Figure VI in the online-only Data Supplement). In contrast, only 32% and 38% of doxorubicinexposed c-kitϩ cells expressed GATA-4 and MEF2C, respectively. There was no significant difference in c-kitϩ cells that were positive for smooth muscle cell marker ␣-smooth muscle actin (Figure VII in the online-only Data Supplement). Although the c-kitϩ cells may not be directly committed to myogenesis in our model, the data suggest that juvenile doxorubicin exposure affects differentiation of cardiac progenitor cells into myocytes and endothelial cells but not into smooth muscle cells.
In contrast to the adult heart, the juvenile heart contains a large population of cardiac progenitor cells. 27 To investigate whether doxorubicin treatment had an effect on cardiac progenitor cells in the juvenile heart, heart sections from mouse pups at 12 days of age were stained for the presence of c-kit. We found that doxorubicin-exposed mice had significantly fewer c-kitϩ cells ( Figure 7A and 7B) , suggesting that doxorubicin might be harmful to cardiac progenitor cells. Hearts from saline-injected mice contained many clusters of c-kitϩ cells, which are thought to reflect intense expansion of progenitor cells. 28 In contrast, hearts of doxorubicin-injected pups had fewer clusters of cells positive for c-kit, suggesting that doxorubicin might inhibit proliferation of cardiac progenitor cells. The cell cycle inhibitor p16
INK4a was significantly upregulated in c-kitϩ cells in doxorubicin-exposed hearts at 12 days of age ( Figure 7C and 7D) . Cardiac progenitor cells isolated from hearts of doxorubicin-treated mice also incorporated less BrdU into the DNA in vitro compared with saline ( Figure 7E ), consistent with reduced proliferation. This suggests that juvenile doxorubicin treatment might have permanently reduced the number of resident progenitor cells in these hearts.
To further investigate the effect of doxorubicin treatment on proliferation of cardiac progenitor cells, we isolated c-kitϩ cells from mouse hearts and treated them with doxorubicin for 72 hours. Treatment of cardiac progenitor cells with 10 or 100 nmol/L doxorubicin attenuated proliferation by 40% and 50%, respectively ( Figure 8A ). In parallel experiments, doxorubicin did not induce cell death at these concentrations, confirming that the reduced number of cells was not due to cell death ( Figure  8B ). Inhibition of proliferation was also confirmed by BrdU incorporation studies, in which fewer doxorubicin-treated cells incorporated BrdU into the DNA ( Figure 8C ). Although an equal number of cells were plated before treatment, wells containing cells treated with saline always had significantly more cells after 72 hours compared with doxorubicin-treated cells ( Figure XIII in the online-only Data Supplement). Doxorubicin treatment also reduced telomerase activity ( Figure 8D ) and induced expression of the senescence marker p16
INK4a
( Figure 8E and 8F) , suggesting that doxorubicin induces senescence in cardiac progenitor cells.
Discussion
Several laboratories have identified resident progenitor cells in the heart that have the capacity to differentiate into the various cardiac cells both in vitro and in vivo. 14,29 -31 These cells are thought to exist in the heart to facilitate growth during adolescence and to provide a mechanism for minor repair. Senescence and death of cardiac progenitor cells correlate with development of heart failure. 32 That children are at higher risk for late-onset cardiotoxicity than adults could be explained by the fact that the heart is still growing and very likely contains more cardiac progenitor cells than the adult myocardium. C-kit-positive cells are present in juvenile human hearts, and it was reported that c-kit-positive cells were more abundant in children with congenital heart disease and that this increase correlated with an increase in apoptotic myocytes. 33 Thus, stress to the young human heart appears to induce mobilization of progenitor cells to the damaged myocardium. Our studies are currently limited to the mouse, but it will be important to verify our findings in human hearts.
Progenitor cells migrate into the border zone after MI, where they participate in myocardial regeneration, blood vessel formation, and remodeling. 19, 20, 34 We found a reduction in the number of c-kitϩ progenitor cells in juvenile mouse hearts after doxorubicin treatment, which correlated with fewer c-kitϩ cells in the border zone of an infarct in the adults compared with saline-treated mice. These mice were more susceptible to MI, with greater infarcts and increased mortality. Interestingly, mice heterozygous for a defective c-kit receptor had a reduced number of c-kitϩ cells in the infarcted heart, which also correlated with increased injury and mortality after MI. 34 Clearly, functional c-kitϩ progenitor cells are important for repairing a heart in response to stress such as MI. Our findings suggest that juvenile doxorubicin treatment has permanently reduced the number of cardiac progenitor cells and reduced their differentiation in response to injury. Thus, a minor ischemic event that would cause minimal or no damage in a healthy person with functional progenitor cells might result in more significant damage in a person with fewer progenitor cells migrating to and differentiating into cardiac cells at the site of injury. Accumulation of such stresses over time may be one of the factors that predispose children exposed to anthracyclines to late-onset cardiomyopathy. Interestingly, studies have reported that survivors of Hodgkin lymphoma were at increased risk of an infarction and had an increased risk of dying from it. 35, 36 These studies also found that the risks were greater in patients treated with anthracyclines when young than in patients who had been treated at older ages.
Doxorubicin induces senescence by reducing telomerase activity in many different cell types. 37, 38 Telomerase activity is also essential for proliferation of pluripotent stem cells and for certain tissue-specific self-renewing stem cells. 32, 39 Neural stem cells isolated from telomerase-deficient mice were incapable of expansion in vitro, suggesting that telomere function is important for proliferation of stem cells. 40 Interestingly, these mice had a reduced number of resident neuronal stem cells that had impaired proliferation. Heart biopsies from old patients with heart failure showed that c-kitϩ progenitor cells had undergone senescence and substantial telomeric shortening, suggesting that these cells can no longer compensate for lost myocytes and therefore may exacerbate the development of heart failure. 32 Thus, telomerase in cycling progenitor cells counters progressive shortening of the telomeres and promotes growth and survival of progenitor cells.
In this study, doxorubicin exposure had long-lasting effects on vascular development, resulting in a vascular tree with fewer ramifications, thereby limiting the capacity to respond to increased demand. This is not simply a developmental defect but also a reflection of limited progenitor capacity because neovascularization after MI was also impaired. Similarly, c-kit mutant mice had reduced angiogenesis after MI. 34 Neovascularization in the border zone after an infarction is an important process to prevent the development of left ventricular remodeling and deterioration to heart failure. Our results suggest that juvenile doxorubicin treatment particularly affects the microvasculature and implies that childhood doxorubicin exposure puts the adult heart at greater risk for ischemic injury due to a barely adequate blood supply. Moreover, defective c-kitϩ cells can affect the myofibroblast repair response after MI, which is important for stabilization of the scar. 41 Because we observed a reduction in the formation of ␣-smooth muscle actin-positive cells in the border zone after MI in the doxorubicin-treated mice, it is possible that doxorubicin exposure has affected the function of the myofibroblasts.
Occasionally, the doxorubicin-treated mice died of cardiac rupture. This is likely attributable to insufficient angiogenesis, which is essential for the repair process and function of the fibroblasts. After an infarction, wound healing ensues, a complex process that involves inflammation, new tissue formation, and remodeling. A defect in infarct healing and remodeling can cause cardiac rupture. 42 Moreover, endothelial progenitor cells are recruited to ischemic regions, improving neovascularization, 43 and it is likely that doxorubicin reduces the pools of other progenitor cells, including endothelial progenitor cells. It is also possible that doxorubicin exposure has impaired the heart's ability to produce and secrete homing factors that will attract progenitor cells to the site of injury or has made the heart a hostile environment that prevents implantation of circulating progenitor cells. This has important implications not only for anthracycline cardiomyopathy but for other childhood exposures that may affect progenitor cell pools.
Our model provides new insight into the mechanism of late-onset cardiotoxicity in mice. However, the similarity and relevance of this model to anthracycline-induced cardiomyopathy in humans are currently unknown and need to be determined. In addition, because the focus of this study was on late-onset cardiotoxicity, we limited this study to the heart, and we did not examine other tissues. Our findings suggest that antecedent doxorubicin exposure has lasting effects on the progenitor cells that participate in cardiac repair and neovascularization. Progenitor cells have therapeutic poten- Figure 8 . Doxorubicin (DOX) treatment inhibits proliferation of isolated cardiac progenitor cells. Cells were treated with doxorubicin for 72 hours and then assessed for cell proliferation by MTT assay (nϭ3) (A) and cell death by trypan blue exclusion assay (nϭ3) (B). C, Cells were treated with 100 nmol/L doxorubicin, and proliferation was determined by BrdU incorporation (nϭ4). D, Cells were exposed to vehicle or 100 nmol/L doxorubicin for 72 or 96 hours and then assayed for telomerase activity with the TRAP assay (nϭ3). E, Isolated cardiac progenitor cells were treated with 100 nmol/L doxorubicin for 72 hours and then fixed and stained for the presence of c-kit and p16 INK4a . F, Quantification of p16 INK4a -positive cells (nϭ4).
tial, and exogenously administered stem cells have been shown to successfully engraft and improve left ventricular function in animal models of MI. 44, 45 Thus, it will be important to explore whether replacing or protecting the cardiac progenitor cells will ameliorate late-onset anthracycline-induced cardiotoxicity.
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